Table 3. Treatment efficacy in the DEB-BACE group.
| Items | DEB-BACE treatment | Final outcomes |
||
|---|---|---|---|---|
| 1st cycle | 2nd cycle | 3rd cycle | ||
| Treated patients, No. | 17 | 6 | 2 | 17 |
| MPE response, No. (%) | ||||
| CR, No. (%) | 11 (64.7) | 2 (33.3) | 1 (50.0) | 14 (82.4) |
| PR, No. (%) | 5 (29.4) | 4 (66.7) | 1 (50.0) | 3 (17.6) |
| Failure, No. (%) | 1 (5.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Overall efficacy, No. (%) | 16 (94.1) | 6 (100.0) | 2 (100.0) | 17 (100.0) |
| ECOG score, No. (%) | ||||
| Improved | 11 (64.7) | 1 (16.7) | 0 (0.0) | 12 (70.6) |
| Stable | 6 (35.3) | 5 (83.3) | 2 (100.0) | 5 (29.4) |
DEB-BACE, drug-eluting beads bronchial arterial chemoembolization; MPE, malignant pleural effusion; CR, complete remission; PR, partial remission; Overall efficacy = CR + PR; ECOG, Eastern Cooperative Oncology Group.